Aim: The top 100 medicines having the highest annual average salesbetween the years 2006 and 2015, had exceeded one-fourth of thetotal pharmaceutical market’s value in these years. We aimed to studythe status of biotechnological medicines among these medicines andevaluate the effects of policy interventions on their sales.Methods: Sales of all medicines on an annual average value basis werecalculated. The top 100 medicines with the highest annual averagesales were included in the study. Time series analysis has been used forprospective estimations.Results: Up to 2007 biotechnological medicines had not been in thetop ten medicines; it increased dramatically after 2007 and in 2016,the sales of biotechnological medicines reached to 82% in top 10 salesin Turkey. On the other hand the number of biotechnological medicinesamong the top 100 medicines was 4 in 2003; it reached to 27 in2016. However the number of biotechnological medicines in the top10 medicines was 1 in 2003 and it reached to 8 in 2016.Conclusion: The shares of biotechnological medicines in both the totalpharmaceutical market and in the group of medicines with high salesare increasing every year. New policies should be developed to ensurethe stability of the reimbursement system.